

---

To claim CME credit, complete this case-based posttest online at <http://www.aad.org/olc>. Note: CME quizzes are available after the first of the month in which the article is published. A minimum score of 70% must be achieved to claim CME credit. If you have any questions, please contact the Member Resource Center of the American Academy of Dermatology toll-free at (866) 503-SKIN (7546), (847) 240-1280 (for international members), or by e-mailing [mrc@aad.org](mailto:mrc@aad.org).

## CME examination

Identification No. JA0519

May 2019 issue of the Journal of the American Academy of Dermatology.

Freites-Martinez A, Shapiro J, Goldfarb S, Nangia J, Jimenez JJ, Paus R, Lacouture ME. J Am Acad Dermatol 2019;80:1179-96.

*Directions for questions 1-4: Choose the single best response.*

A 38-year-old woman was diagnosed with stage III breast cancer and will receive taxane-based chemotherapy. The patient is concerned about chemotherapy-induced alopecia and consulted for any possible strategy to prevent her hair loss.

1. What is the optimal strategy to prevent cytotoxic chemotherapy-induced alopecia in this patients with breast cancer?
  - a. Minoxidil foam 5%
  - b. Platelet-rich plasma
  - c. A scalp cooling device
  - d. Finasteride 2.5 mg
  - e. Spironolactone 50 mg
2. Which of the following options is one of the primary contraindications for the strategy chosen above?
  - a. Breast cancer
  - b. Hormone-sensitive tumors
  - c. Hematologic malignancies
  - d. Childbearing age
  - e. Hyperkalemia

A 68-year-old man was diagnosed with metastatic colorectal adenocarcinoma. The patient had been receiving cetuximab for 3 months and presented to the clinic with a painful rash on his scalp and face. His dermatologic examination revealed thick yellow odorous plaque and crusting on his scalp and beard areas. The patient did not have any other dermatologic or systemic symptoms.

3. Which treatment option is the most appropriate in this patient?
  - a. Topical antibiotic
  - b. Topical low-potency corticosteroids
  - c. Culture/sensitivity-driven oral antibiotics and topical corticosteroids
  - d. Minoxidil 5%
  - e. Anticancer therapy hold
4. Which other hair disorder do you NOT expect to see in patients who are taking cetuximab?
  - a. Eyelash trichomegaly
  - b. Hirsutism
  - c. Pigmentary hair changes
  - d. Eyebrow trichomegaly
  - e. Pattern alopecia (similar to androgenetic type)